Duke professors argue ACOs haven’t worked

Duke University professors Kevin Schulman, MD, and Barak Richman, JD, PhD, called on the CMS Innovation Center to focus on telemedicine and wearable devices, rather than accountable care organizations (ACOs) which integrate hospitals, to reduce the cost of care.

In a JAMA Viewpoints article, Schulman and Richman said ACO programs like the Pioneer ACO model “have failed to produce needed efficiencies." They argued the problems can’t be blamed on poor implementation, with the Medicare Shared Savings Program including 220 participating organizations and another 32 involved in Pioneer ACO. The real issue, they wrote, was an incorrect hypothesis about the cost savings of ACOs.

“There have been several iterations of the ACO concept, and none appears to have meaningfully reduced the cost of care,” Schulman and Richman wrote. “Even though mere nominal savings would be important, Medicare’s financial fragility and the increasing burden of healthcare costs for the baby boom generation demand policies that bend the cost curve more substantially.”

They went as far as to say CMS should “reject the ACO hypothesis and end its interest in hospital-led strategies in healthcare.”

For more on how telemedicine and wearable devices would fit into this post-ACO strategy, click on the link below:
 

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.